



THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia

Author(s): Henry A. Nasrallah, MD; John W. Newcomer, MD; Robert Risinger, MD; Yangchun Du, PhD; Jacqueline Zummo, MPH, MBA; Anjana Bose, PhD; Srdjan Stankovic, MD, MSPH; Bernard L. Silverman, MD; and Elliot W. Ehrich, MD

DOI Number: 10.4088/JCP.15m10467

List of Supplementary Material for the article

1. [eTable 1](#) Values Used to Define Shifts From Normal and High From Baseline
2. [eTable 2](#) Shifts in Prolactin

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1. Values used to define shifts from normal and high from baseline.

Parameter	Normal Value	High Value
Total cholesterol (mg/dL)	<200	≥240
LDL cholesterol (mg/dL)	<100	>160
HDL cholesterol (mg/dL)	≥40	<40
Triglycerides (mg/dL)	<150	≥200
Glycated hemoglobin (g/dL)	4.0–6.0	>6.5
Plasma glucose (mg/dL)	<100	≥126
Prolactin (ng/mL) – males	<4.0	≥15.2
Prolactin (ng/mL) – females	<4.8	≥23.3

Supplementary eTable 2. Shifts in Prolactin

	Shift From low/Normal at Baseline to High/3xULN at any Post Baseline Assessment			Shift from High/3xULN at Baseline to low/Normal at Last Post Baseline Assessment		
Parameter	Aripiprazole Lauroxil		Placebo	Aripiprazole Lauroxil		Placebo
	441 mg n/m (%)	882 mg n/m (%)		441 mg n/m (%)	882 mg n/m (%)	
Prolactin (Male)	3/105 (2.9)	4/111(3.6)	26/102 (25.5)	19/22 (86.4)	12/17 (70.6)	9/20 (45)
Prolactin (Female)	6/38 (15.8)	3/41 (7.3)	14/41 (34.1)	12/20 (60)	11/19 (57.9)	6/20 (30)

n is the number of patients in each category; m is the total number of patients with non-missing numeric values at baseline and any post-baseline visit for each treatment group.